Current landscape of systemic therapies for hepatocellular carcinoma
| Treatment line | Treatment | Pharmacological targets | Clinical trial and ID | Results |
|---|---|---|---|---|
| First-line | Sorafenib (vs. placebo) | Multiple kinases: VEGFR, PDGFR, etc. | SHARP107 (NCT00105443) 2008/7 | OS: 10.7 vs. 7.9 mo (HR 0.69, 95% CI 0.55–0.87, P < 0.001); TTP: 5.5 vs. 2.8 mo (P < 0.001) |
| Lenvatinib (vs. sorafenib) | Multiple kinases: VEGFR, FGFR, etc. | REFLECT108 (NCT01761266) 2018/3 | OS 13.6 vs. 12.3 mo (HR 0.92, 95% CI 0.79–1.06); PFS 7.4 vs. 3.7 mo (HR 0.66, P < 0.001); ORR 24% vs. 9% (P < 0.001) | |
| Atezolizumab + bevacizumab (vs. sorafenib) | PD-L1 + VEGF | IMbrave15041 (NCT03434379) 2020/3 | OS: HR 0.58 (0.42–0.79, P < 0.001); PFS: 6.8 vs. 4.3 mo (HR 0.59, P < 0.001); ORR: 27.3% vs. 11.9% (CR 5.5% vs. 0%) | |
| Tremelimumab + durvalumab (vs. sorafenib) | CTLA-4 + PD-L1 | HIMALAYA109 (NCT03298451) 2022/8 | OS 16.4 vs. 13.8 mo (HR 0.78, P = 0.0035); ORR 20.1% vs. 5.1% (CR 3.1% vs. 0%) | |
| Camrelizumab + rivoceranib (vs. sorafenib) | PD-1 + VEGFR2 | CARES-310110 (NCT03764293) 2023/8 | OS: 22.1 vs. 15.2 mo (HR 0.62, 95% CI 0.49–0.80, P < 0.0001); PFS: 5.6 vs. 3.7 mo (HR 0.52, 95% CI 0.41–0.65, P < 0.0001); ORR: 25.4% vs. 5.9% | |
| Tislelizumab (vs. sorafenib) | PD-1 | RATIONALE-301111 (NCT03412773) 2023/12 | OS: 15.9 vs. 14.1 mo (HR 0.85, 95% CI 0.71–1.02); PFS: 2.1 vs. 3.4 mo (HR 1.11, 95% CI 0.92–1.33); ORR: 14.3% vs. 5.4% (95% CI 1.57–4.85, P < 0.001) | |
| Nivolumab + ipilimumab (vs. lenvatinib /sorafenib) | PD-1 + CTLA-4 | CheckMate-9 DW112 (NCT04039607) 2025/5 | OS 23.7 vs. 20.6 mo (HR 0.79, 95% CI 0.65–0.96, P = 0.018); ORR 36% vs. 13% (P < 0.0001) | |
| Second-line | Ramucirumab (vs. placebo) | VEGFR2 | REACH113 (NCT01140347) 2015/7 | OS: 9.2 vs. 7.6 mo (HR 0.87, 95% CI 0.72–1.05, P = 0.14); PFS: 2.8 vs. 2.1 mo (HR 0.63, 95% CI 0.52–0.75, P < 0.0001); ORR: 7% vs. <1% (P < 0.0001) |
| Regorafenib (vs. placebo) | Multiple kinases: KIT, RET, etc. | RESORCE114 (NCT01774344) 2017/1 | OS: 10.6 vs. 7.8 mo (HR 0.63, 95% CI 0.50–0.79, P < 0.0001); PFS: 3.1 vs. 1.5 mo (HR 0.46, 95% CI 0.37–0.56); ORR: 11% vs. 4% (P = 0.0047); TTP: 3.2 vs. 1.5 mo (HR 0.44) | |
| Cabozantinib (vs. placebo) | Multiple kinases: VEGFR, MET, etc. | CELESTIAL115 (NCT01908426) 2018/7 | OS: 10.2 vs. 8.0 mo (HR 0.76, 95% CI 0.63–0.92, P = 0.005); PFS: 5.2 vs. 1.9 mo (HR 0.44, 95% CI 0.36–0.52, P < 0.001); ORR: 4% vs. <1% (P = 0.009) | |
| Nivolumab | PD-1 | CheckMate 040116 (NCT01658878) 2017/6 | OS: 13.2 mo in sorafenib progressor cohort; ORR: 20% (sorafenib progressors 21%) | |
| Pembrolizumab | PD-1 | KEYNOTE-394117 (NCT03062358) 2023/3 | OS: 14.6 vs. 13.0 mo (HR 0.79, 95% CI 0.63–0.99, P = 0.018); PFS: 2.6 vs. 2.3 mo (HR 0.74, 95% CI 0.60–0.92, P = 0.0032); ORR: 12.7% vs. 1.3% (P < 0.0001) |
CI, confidence interval; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; FGFR, fibroblast growth factor receptor; HR, hazard ratio; KIT, KIT proto-oncogene receptor tyrosine kinase; MET, MET proto-oncogene receptor tyrosine kinase; ORR, objective response rate; OS, median overall survival; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PDGFR, platelet-derived growth factor receptor; PFS, progression-free survival; RET, rearranged during transfection; TTP, time to progression; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.